13365-41-8

Usage

Uses

Used in Pharmaceutical Industry:
2-Methyl-2-(2-naphthyl)propanoic acid is used as an analgesic for its pain-relieving properties, making it suitable for individuals suffering from mild to moderate pain.
2-Methyl-2-(2-naphthyl)propanoic acid is used as an antipyretic to reduce fever by lowering the body's temperature.
2-Methyl-2-(2-naphthyl)propanoic acid is used as an anti-inflammatory agent to decrease inflammation and associated discomfort in conditions such as arthritis, menstrual cramps, and gout.
2-Methyl-2-(2-naphthyl)propanoic acid is used in the treatment of specific types of arthritis, such as osteoarthritis and rheumatoid arthritis, due to its ability to manage inflammation and associated pain.
2-Methyl-2-(2-naphthyl)propanoic acid is used for the management of menstrual cramps, providing relief from the pain and inflammation associated with menstruation.
2-Methyl-2-(2-naphthyl)propanoic acid is used in the treatment of gout, helping to alleviate the severe pain and inflammation caused by uric acid crystals in the joints.
While generally well-tolerated, 2-Methyl-2-(2-naphthyl)propanoic acid may cause gastrointestinal irritation or bleeding in some individuals, and its dosage is carefully determined based on the condition being treated and the patient's specific needs.

Upstream product

• 69849-14-5 2-methyl-2-(naphthalen-2-yl)propanenitrile 
• 74-83-9 methyl bromide 
• 26159-40-0 (+-)-2-[2]naphthyl-propionic acid 
• 228411-14-1 2,2-dimethyl-(2-naphthyl)acetic acid benzyl ester 

Downstream Products

• 228408-75-1 3-[2'-(R,S)-(dimethyl)-naphthylacetylamino-3'-[4''-(1'''-carboxy-1'''-methyl)ethyl]benzene]propanoylamino-1-(4-methoxybenzyl)-4-methyl-2-pyridone 
• 228408-75-1 2-{4-[(S)-2-[1-(4-Methoxy-benzyl)-4-methyl-2-oxo-1,2-dihydro-pyridin-3-ylcarbamoyl]-2-(2-methyl-2-naphthalen-2-yl-propionylamino)-ethyl]-phenyl}-2-methyl-propionic acid 
• 228408-75-1 2-{4-[(R)-2-[1-(4-Methoxy-benzyl)-4-methyl-2-oxo-1,2-dihydro-pyridin-3-ylcarbamoyl]-2-(2-methyl-2-naphthalen-2-yl-propionylamino)-ethyl]-phenyl}-2-methyl-propionic acid 

Relevant academic research and scientific papers

Palladium(II)-Catalyzed C(sp2)-H Carbonylation of Sterically Hindered Amines with Carbon Monoxide

A palladium-catalyzed, amine-directed C(sp2)-H carbonylation of α,α-disubstituted benzylamine under 1 atm of CO for the facile synthesis of sterically hindered benzolactam has been developed. The key to success is the use of 2,2,6,6-tetramethyl-1-piperidinyloxy as the crucial sole oxidant. The synthetic utility of this transformation has been demonstrated by the first concise synthesis of the natural product spiropachysin-20-one.

Amide-Directed C?H Sodiation by a Sodium Hydride/Iodide Composite

A new protocol for amide-directed ortho and lateral C?H sodiation is enabled by sodium hydride (NaH) in the presence of either sodium iodide (NaI) or lithium iodide (LiI). The transient organosodium intermediates could be transformed into functionalized aromatic compounds.

Nonpeptidic, monocharged, cell permeable ligands for the p56lck SH2 domain

p56lck is a member of the src family of tyrosine kinases and plays a critical role in the signal transduction events that lead to T cell activation. Ligands for the p56lck SH2 domain have the potential to disrupt the interaction of p56lck with its substra

Src family SH2 domain inhibitors

This invention relates to compounds of formula (1): wherein Ring a, A, B, C, D, E, R and Q are defined herein. These compounds possess the ability to disrupt the interaction between regulatory proteins possessing one or more SH2 domains and their native ligands.

Use of 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine derivatives as free radical scavengers

The invention concerns the use of a compound of formula (I) STR1 wherein R and R1, each independently, represent a hydrogen atom or a methyl group, and its pharmaceutically acceptable acid addition salts, as free radical scavengers. The pharmaceutical compositions containing these compounds may be employed in the treatment and/or prevention of pathological processes involving cell damage due to the formation of free radicals. The invention also concerns the compounds of formula (I) wherein at least one of R and R1 is methyl, which are new compounds, as well as the process for the preparation thereof and the pharmaceutical compositions containing them.